Clinical Trial Update: 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Osimertinib with 18F-FDG PET to assess glucose utilization in EGFR-activated recurrent glioblastoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Tagrisso (osimertinib) (osimertinib)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: EGFR Gene Amplification, EGFR Gene Mutation | Phase 2 | Status: COMPLETED